SAGE's Cookie Policy
Close 

To enhance your experience on our site, SAGE stores cookies on your computer. By continuing you consent to receive cookies.

Learn More

Therapeutic Advances in Drug Safety

Editor-in-Chief:
Flinders University, Adelaide, Australia
Editor:
SAGE Publications Ltd, UK
Associate Editors:
J&J Pharmaceutical Research & Development, USA
Univeristy of Otago Christchurch, New Zealand
NHS Grampian, Aberdeen, UK
York Hospitals NHS Trust, UK
TGRD (Europe), London, UK
 
2013 SJR (SCImago Journal Rank) Score: 0.553
2013 Ranking: 112/247 in Pharmacology (Medical) (Scopus®)
Source: SCImago 2013 Journal Rankings

Therapeutic Advances in Drug Safety delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies pertaining to the safe use of drugs in patients.

The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in drug safety, providing a forum in print and online for publishing the highest quality articles in this area. The editors welcome articles of current interest on research across all areas of drug safety, including therapeutic drug monitoring, pharmacoepidemiology, adverse drug reactions, drug interactions, pharmacokinetics, pharmacovigilance, medication/prescribing errors, risk management, ethics and regulation.

It publishes expert opinion reviews (including single-drug and drug class reviews), narrative reviews and analysis of published guidelines (as editorials or reviews). Original research manuscripts of well-designed trials are also welcomed as are case reports/case series. The journal strongly encourages the submission of original research with positive or negative results. Animal studies and in vitro studies that may have a bearing on drug safety in humans may also be considered for publication.

The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees - a first editorial decision is generally reached within 3 weeks of submission. Online publication of articles occurs within 7 weeks from acceptance. Further information for contributors is provided on the back pages of each issue and online.

For all commercial sales and sponsorship enquiries, including advertising, reprints and supplements, please contact:

Commercial Sales Team, London, UK
Tel. +44 20 7336 1205
Email. reprints@sagepub.co.uk

This journal is a member of the Committee on Publication Ethics (COPE).

Subscription Information :
Institutional Subscription, Combined (Print & E-access) $1,181.00
Institutional Subscription, E-access $1,063.00
Institutional Subscription, Print Only $1,157.00
Individual Subscription, Print Only $155.00

Individual articles are available for immediate purchase online (See View Full-Text icon above). Print copies of individual issues can be purchased by contacting the SAGE Journals Customer Service department journals@sagepub.com 1-800-818-7243.

If you are eligible for non-standard pricing please contact Journals Customer Service department journals@sagepub.com 1-800-818-7243 for a price quote.

Institutional, Single Print Issue $212.00
Individual Single Print Issue $34.00
Frequency: Bi-monthly eISSN: 2042-0994 ISSN: 2042-0986
Months of Distribution: February , April , June , August , October , December Current Volume: 5 Current Issue: 4
Other Titles In:
-
-
-

Product Type

All

Subject Areas

All